Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LM716 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LJM716 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LM716 | DRUG | - |
Inclusion Criteria: 1. Patients with the following indications: i) (Dose escalation part only): HER2 overexpressing locally advanced/ metastatic breast cancer or gastric cancer for which no effective treatment option exists: * For breast cancer: documented 3+ by immunohistochemistry, or ampl...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
LM716 is an investigational small molecule developed by Novartis AG for the treatment of neoplasms, specifically advanced solid tumors. It is in Phase 1 clinical development in oncology and has been studied in a biomarker-selected patient population. LM716 has not been approved by the FDA and remains an investigational agent.
LM716 is being studied for use in patients with neoplasms, including advanced solid tumors. The clinical program has focused on biomarker-selected patients, meaning enrollment has been limited to those whose tumors express a specific biomarker. It is investigational and has not been approved for any indication.
LM716 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis is the sponsor of the clinical program evaluating LM716 in oncology, including the Phase 1 study conducted in Japanese patients with advanced solid tumors.
LM716 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The completed study enrolled 12 patients and was an uncontrolled, non-randomized, open-label trial, so it did not include a placebo or comparator arm.
LM716 has been evaluated in one completed Phase 1 trial, NCT01911936, titled A Phase I Study of LJM316 in Japanese Patients With Advanced Solid Tumors. The study enrolled 12 patients aged 18 years and older in Japan and included both male and female participants. No trials of LM716 are currently active.
Yes, LM716 and LJM716 refer to the same investigational compound from Novartis. The completed Phase 1 trial in Japanese patients with advanced solid tumors is registered under the name LJM716, while LM716 is the shorter form of the same drug name used in reference materials.